Optimizing laboratory-based surveillance networks for monitoring multi-genotype or multi-serotype infections
Fig 7
Optimal proportion of severe cases to be subjected to serotyping as the availability of typing resources changes, when seeking to minimize error serotype-specific incidence rates of (A) all HFMD cases and (B) only severe HFMD cases.